We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
The U.S. Federal Trade Commission recently issued a report again criticizing the role that authorized generic drugs sometimes play in patent infringement settlements between branded pharmaceutical manufacturers and their generic counterparts
Soonperhaps by the time you read thisCongress may pass a bill designed to declare so-called "reverse payment" settlements of patent litigation presumptively unlawful
Earlier this month, Federal Trade Commission staff sent letters to four pharmaceutical companies disclosing its current intention not to challenge pharmaceutical litigation settlement agreements
